

In the specification:

Please replace the second paragraph beginning at page 1, line 17 with the following paragraph:

**(Replacement paragraph)** This application is related to U.S. utility applications 10/622932 (~~Attorney Docket No. BPI-187~~) entitled “Treatment of TNF $\alpha$ -Related Disorders Using TNF $\alpha$  Inhibitors,” (~~Attorney Docket No. BPI-188~~) 10/623039 entitled “Treatment of Spondyloarthropathies Using TNF $\alpha$  Inhibitors,” (~~Attorney Docket No. BPI-189~~) 10/623076 entitled “Treatment of Pulmonary Disorders Using TNF $\alpha$  Inhibitors,” (~~Attorney Docket No. BPI-190~~) 10/623065 entitled “Treatment of Coronary Disorders Using TNF $\alpha$  Inhibitors,” (~~Attorney Docket No. BPI-191~~) 10/622928 entitled “Treatment of Metabolic Disorders Using TNF $\alpha$  Inhibitors,” (~~Attorney Docket No. BPI-192~~) entitled “~~Treatment of Anemia Using TNF $\alpha$  Inhibitors,~~” (~~Attorney Docket No. BPI-193~~) 10/623035 entitled “Treatment of Pain Using TNF $\alpha$  Inhibitors,” (~~Attorney Docket No. BPI-194~~) 10/622683 entitled “Treatment of Hepatic Disorders Using TNF $\alpha$  Inhibitors,” (~~Attorney Docket No. BPI-195~~) 10/622205 entitled “Treatment of Skin and Nail Disorders Using TNF $\alpha$  Inhibitors,” (~~Attorney Docket No. BPI-196~~) 10/622210 entitled “Treatment of Vasculitides Using TNF $\alpha$  Inhibitors,” (~~Attorney Docket No. BPI-197~~) 10/623318 entitled “Treatment of TNF $\alpha$ -Related Disorders Using TNF $\alpha$  Inhibitors,” and PCT application PCT/US2003/022566 (~~Attorney Docket No. BPI-187PC~~) entitled “Treatment of TNF $\alpha$ -Related Disorders,” all of which are filed on even date herewith. The entire contents of each of these patents and patent applications are hereby incorporated herein by reference.